Permanent Vascular Access: A Nephrologist's View

Windus, David W.

doi:10.1016/s0272-6386(12)80391-x

Cited by 278 publications

(150 citation statements)

References 95 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…However, stenosis and thrombosis substantially contribute to the difficulty in maintaining the patency of AVF. Stenoses account for over 80% of AVF thromboses; thromboses are responsible for 80% to 85% of AVF failures (1). Stenosis of vascular access is histologically characterized by intimal hyperplasia, which results from the initial proliferation of vascular smooth muscle cells (VSMCs) and the subsequent migration of VSMCs from the media to the intima, and exuberant synthesis of extracellular matrix, which leads to further intimal expansion (2).…”

mentioning

confidence: 99%

Functional Polymorphisms in Matrix Metalloproteinases-1, -3, -9 are Associated with Arteriovenous Fistula Patency in Hemodialysis Patients

Lin¹,

Wu²,

Chung³

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Functional Polymorphisms in Matrix Metalloproteinases-1, -3, -9 are Associated with Arteriovenous Fistula Patency in Hemodialysis Patients

Lin¹,

Wu²,

Chung³

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Malfunction of vascular access usually presents with inadequate blood flow because of stenosis or thrombosis of the venous outflow tract (2). Approximately 80 to 85% of AV access failures arise from AV access thromboses, more than 80% of which result from AVF stenoses (3). An access flow (Qa), Ͻ500 ml/min was associated with an increased risk for access failure and predictive of poorer unassisted patency of native AVF (4).…”

mentioning

confidence: 99%

Far-Infrared Therapy

Lin¹,

Chang²,

Lai³

et al. 2007

Journal of the American Society of Nephrology

136

135

View full text Add to dashboard Cite

“…Recent data indicate that the majority of patients on hemodialysis in the United States have prosthetic graft fistulas. The most frequent complications of prosthetic graft fistulas are thrombosis and stenosis 135. Endovascular interventions have replaced surgical repair as the primary treatment of the failing or thrombosed vascular access.…”

Section: Discussionmentioning

confidence: 99%

A Reappraisal of Saphenous Vein Grafting

Yuan

Hua

2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

Autologous saphenous vein grafting has been broadly used as a bypass conduit, interposition graft, and patch graft in a variety of operations in cardiac, thoracic, neurovascular, general vascular, vascular access, and urology surgeries, since they are superior to prosthetic veins. Modified saphenous vein grafts (SVG), including spiral and cylindrical grafts, and vein cuffs or patches, are employed in vascular revascularization to satisfy the large size of the receipt vessels or to obtain a better patency. A loop SVG helps flap survival in a muscle flap transfer in plastic and reconstructive surgery. For dialysis or transfusion purposes, a straight or loop arteriovenous fistula created in the forearm or the thigh with an SVG has acceptable patency. The saphenous vein has even been used as a stent cover to minimize the potential complications of standard angioplasty technique. However, the use of saphenous vein grafting is now largely diminished in treating cerebrovascular disorders, superior vena cava syndrome, and visceral revascularization due to the introduction of angioplasty and stenting techniques. The SVG remains the preferable biomaterial in coronary artery bypass, coronary ostioplasty, free flap transfer, and surgical treatment of Peyronie disease. Implications associated with saphenous vein grafting in vascular access surgery for the purpose of dialysis and chemotherapy are considerable. Vascular cuffs and patches have been developed as an important and effective means of enhancing the patency rates of the grafts by linking the synthetic material to the receipt vessel. In addition, saphenous veins can be a cell source for tissue engineering. We review the versatile roles that saphenous vein grafting has played as well as its current status in therapy.

show abstract

Permanent Vascular Access: A Nephrologist's View

Cited by 278 publications

References 95 publications

Functional Polymorphisms in Matrix Metalloproteinases-1, -3, -9 are Associated with Arteriovenous Fistula Patency in Hemodialysis Patients

Functional Polymorphisms in Matrix Metalloproteinases-1, -3, -9 are Associated with Arteriovenous Fistula Patency in Hemodialysis Patients

Far-Infrared Therapy

A Reappraisal of Saphenous Vein Grafting

Contact Info

Product

Resources

About